X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
3.430
-0.280 (-7.55%)
Feb 11, 2026, 4:00 PM EST - Market closed

X4 Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
33.982.56---3
Cost of Revenue
5.70.8----
Gross Profit
28.281.76---3
Selling, General & Admin
46.2861.5235.5127.0224.720.94
Research & Development
73.781.6472.0261.0650.6541.93
Operating Expenses
119.98143.16107.5288.0875.3562.87
Operating Income
-91.7-141.4-107.52-88.08-75.35-59.87
Interest Expense
-8.99-8.77-5.78-3.99-3.64-2.69
Interest & Investment Income
3.865.774.580.220.010.27
Currency Exchange Gain (Loss)
-0.33-0.330---4.37
Other Non Operating Income (Expenses)
9.572.597.63-2.50.064.84
EBT Excluding Unusual Items
-87.6-142.14-101.09-94.35-78.92-61.82
Impairment of Goodwill
-----9.76-
Gain (Loss) on Sale of Assets
-105-0.51--
Other Unusual Items
------0.16
Pretax Income
-94.8-37.14-101.09-93.84-88.68-61.98
Income Tax Expense
0.30.310.080.030.020.15
Net Income
-95.1-37.45-101.17-93.87-88.7-62.13
Preferred Dividends & Other Adjustments
---2.5513.94-
Net Income to Common
-95.1-37.45-101.17-96.41-102.64-62.13
Shares Outstanding (Basic)
1676211
Shares Outstanding (Diluted)
1676211
Shares Change (YoY)
141.76%13.08%179.91%146.71%28.25%74.13%
EPS (Basic)
-5.90-5.59-17.07-45.53-119.59-92.84
EPS (Diluted)
-5.90-5.59-17.07-45.53-119.59-92.84
Free Cash Flow
-103.13-131.23-96.57-77.21-71.52-60.18
Free Cash Flow Per Share
-6.40-19.58-16.29-36.46-83.33-89.92
Gross Margin
83.24%68.83%---100.00%
Operating Margin
-269.87%-5529.96%----1995.80%
Profit Margin
-279.86%-1464.61%----2071.03%
Free Cash Flow Margin
-303.50%-5132.07%----2006.00%
EBITDA
-90.37-140.61-107.1-87.57-74.85-59.52
D&A For EBITDA
1.330.80.420.510.50.35
EBIT
-91.7-141.4-107.52-88.08-75.35-59.87
Updated Nov 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q